Abstract

Initially originating as an epidemic respiratory illness in Wuhan, China, COVID-19 eventually spread around the world and has now been declared as a global pandemic disease by the WHO. Our understanding of the pathophysiology of SARS-CoV-2 is evolving with each passage of days. Previously thought to be a respiratory illness resulting in pulmonary complications such as pneumonia, respiratory failure, and acute respiratory distress syndrome now have been found to be causing multiple extra-pulmonary pathologies which includes various degree of autoimmune disorders. Certain group of patients have been found to have autoimmune haemolytic anaemia triggered by COVID-19. We report a case series of five patients who developed COVID-19 induced AIHA which responded dramatically to oral dexamethasone (6mg once daily) initially prescribed for the deteriorating pulmonary function. Therefore, our intuition is dexamethasone prescribed for COVID-19 pneumonitis is beneficial for the rapid recovery of AIHA associated with COVID-19. 

Keywords: COVID-19, Autoimmune Haemolytic Anaemia, United Kingdom

Downloads

Download data is not yet available.
 How to Cite
Dr. Saquib Navid Siddiqui. (2021). Is Standard Oral Dose Dexamethasone (6mg Once Daily) Prescribed For COVID-19 Pneumonitis Treating Autoimmune Haemolytic Anaemia Associated with COVID-19? A Case Series of Five Patients Providing Us with the Answer. International Journal of Innovative Research in Medical Science, 6(01), 73–77. https://doi.org/10.23958/ijirms/vol06-i01/1037

Copyrights & License